CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Biopsy-proven aggressive non-Hodgkin's lymphoma (follicular grade 3, diffuse large cell, mantle cell, or transformed)
  • ✓Relapsed or refractory to prior therapy; must have received at least one prior treatment (radiation, immunotherapy, chemotherapy, or radioimmunotherapy)
  • ✓Measurable disease on imaging at least 2 cm in longest diameter
  • ✓Age ≥18 years
Key exclusion· 13
  • ✕ANC <1,500 cells/mm³
  • ✕Platelet count <100,000/mm³
  • ✕Serum creatinine >2.5 mg/dL
  • ✕AST or ALT >5.0 x ULN

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00179660
NCT00179660Phase 2Completed
CompareCT.gov

A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma

Celgene Corporation·interventional·Posted Sep 16, 2005·Updated Jan 21, 2016

In Brief

A Phase 2 clinical trial evaluating Lenalidomide for Non-Hodgkins Lymphoma. Completed, enrolled 50 participants across 8 sites.

Detailed Summary

To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkins Lymphoma
CountriesUnited States
CollaboratorsPrologue Research International

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartAug 1, 2005
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.8 years ago

Interventions

Lenalidomidedrug

Capsules for oral administration.